| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T136 |
0-74 |
Sentence |
denotes |
• Tocilizumab to mitigate cytokine storm • Prospective observational study |
| T137 |
75-114 |
Sentence |
denotes |
• Severe or critical COVID-19 infection |
| T138 |
115-138 |
Sentence |
denotes |
• 25 to 88 years of age |
| T139 |
139-179 |
Sentence |
denotes |
• N = 21 tocilizumab + standard therapy |
| T140 |
180-239 |
Sentence |
denotes |
• 42.9% had CVD • 4–8 mg/kg or 400 mg tocilizumab i.v. once |
| T141 |
240-368 |
Sentence |
denotes |
• 85.7% received single dose of tocilizumab, 14.3% required second dose within 12 h of first dose • Fever normalized within 24 h |
| T142 |
369-402 |
Sentence |
denotes |
• Reduced O2 therapy requirements |
| T143 |
403-439 |
Sentence |
denotes |
• Minimal improvement in IL-6 levels |
| T144 |
440-468 |
Sentence |
denotes |
• CT lung lesion improvement |
| T145 |
469-537 |
Sentence |
denotes |
• All patients discharged • Limited sample size and no control group |
| T146 |
538-661 |
Sentence |
denotes |
• Tocilizumab treatment in severe COVID-19 cases may improve clinical symptoms in hyperinflammatory state (Xu et al., 2020) |
